Dr. Reddy's gets USFDA’s nod for migraine treatment oral solution

07 May 2020 Evaluate

Dr. Reddy's Laboratories and its subsidiaries have received approval for their NDA, Elyxyb (celecoxib oral solution 25 mg/mL) from the US Food and Drug Administration (USFDA).

ELYXYB (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. ELYXYB is the latest product emerging from Dr. Reddy's portfolio of successful acute migraine treatments. The company is working to commercialize this product through partners.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1279.60 7.60 (0.60%)
18-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.35
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 913.85
Lupin 2118.25
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×